JPH07324027A - Skin-beautifying cosmetic - Google Patents

Abstract

PURPOSE:To obtain a skin-beautifying cosmetic having excellent anti- inflammatory effect, beautifying effect and skin safety and providing excellent feeling to the skin by using a water-soluble UV absorber in combination with a nonsteroidal anti-inflammatory agent and an L-ascorbic acid derivative. CONSTITUTION:This skin-beautifying cosmetic is produced by using a water-soluble UV absorber such as p-aminobenzoic acid in combination with a nonsteroidal anti-inflammatory agent such as indomethacin and an L-ascorbic acid derivative. The water-soluble ultraviolet absorber is, e.g. p-methoxycinnamic acid, 2- phenylbenzimidazole-5-sulfonic acid, salicylic acid derivative, their alkali metal, ammonium or organic amine salts and the nonsteroidal anti-inflammatory agent is, e.g. phenylbutazone, ibuprofen, mefenamic acid, diclofenac sodium, bufexamac or nabumetone. The cosmetic can be used in the form of cream, milky lotion, face lotion, pack, etc.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening cosmetic having an effect of preventing skin inflammation caused by ultraviolet rays and an effect of preventing / suppressing inflammatory pigmentation.

[0002]

2. Description of the Related Art One of the causes of skin inflammation is the penetration of ultraviolet rays (particularly UVB) into the skin. Therefore, in order to prevent inflammation, it is necessary to block the transmission of ultraviolet rays with ultraviolet absorbers, pigments and the like. However, when inflammation occurs, arachidonic acid present in the cell membrane in the skin is released, and various prostaglandins (PG) are released through the cyclooxygenase system.
A class is generated. On the other hand, various leukotrienes (LTs) are also produced by the lipoxygenase system. These chemical transmitters cause vasodilation of arterioles and cause erythema, and also cause inflammatory conditions such as increased vascular permeability and edema.

Further, these chemical transmitters act on melanocytes in various forms and also contribute to melanin synthesis in melanocytes. Melanin produced by the oxidation of tyrosine in melanocytes is transferred to epidermal cells, which changes the skin tone and causes blackening.

[0004] Conventionally, whitening makeup containing a salt of L-ascorbic acid, a fatty acid derivative, hydroquinone monobenzyl ether, hydrogen peroxide, etc. in order to prevent blackening, stains and freckles of the skin and maintain the original white skin. Fees are proposed. On the other hand, for the purpose of suppressing inflammation caused by ultraviolet rays, cosmetics containing fine particle titanium oxide that blocks ultraviolet rays, an ultraviolet absorber, and the like have also been proposed.

However, when an L-ascorbic acid derivative is blended in these whitening cosmetics, the storage stability is insufficient, or the anti-inflammatory and whitening effects due to ultraviolet rays are often not sufficiently observed. On the other hand, blending hydroquinone monobenzyl ether or the like into a whitening cosmetic has the effect of lightening dark skin, but has the drawback of causing a problem in terms of skin safety.

[0006] Cosmetics containing fine particle titanium oxide, an ultraviolet absorber and the like have an effect of preventing inflammation by suppressing the penetration of ultraviolet rays into the skin, but the effect is not sufficient. Further, since a lipophilic ultraviolet absorber has been used conventionally, it has a sticky feel when applied to the skin, and the usability is not satisfactory.

When a water-soluble ultraviolet absorber is blended alone, it is possible to block ultraviolet rays to some extent, but it is not perfect, and it suppresses subsequent inflammation and pigmentation when a large amount of ultraviolet rays are irradiated. I can't.

On the other hand, when a non-steroidal anti-inflammatory drug is mixed, the erythema due to ultraviolet rays is remarkably suppressed by mainly inhibiting the cyclooxygenase system, but the amount of the mixture causes itch reaction, mild rash, etc. There was a safety issue. As described above, it is extremely difficult to obtain a whitening cosmetic composition having excellent anti-inflammatory effect and whitening effect, high skin safety, and good feeling in use.

[0009]

In view of such a situation, the inventors of the present invention have conducted intensive studies to improve the drawbacks of the prior art, and as a result, the invention described below has an excellent anti-inflammatory effect and a whitening effect. Further, they have found that the whitening cosmetic composition has high skin safety and excellent usability, and thus completed the present invention.

That is, an object of the present invention is to provide a whitening cosmetic composition which is excellent in ultraviolet absorption effect, inflammation suppressing effect and whitening effect, has high skin safety and is excellent in usability.

The above object is achieved by a whitening cosmetic composition containing a water-soluble ultraviolet absorber, a nonsteroidal anti-inflammatory drug, and an L-ascorbic acid derivative.

As the water-soluble ultraviolet absorber used in the present invention, para-aminobenzoic acid, para-methoxycinnamic acid, 2
-Phenylbenzimidazole-5-sulfonic acid, salicylic acid derivatives and salts of alkali metals, ammonia or organic amines, but not limited to these. These water soluble UV absorbers have 1
They may be used alone or in combination of two or more.

The water-soluble UV absorber, by its nature, suppresses inflammation by blocking the transmission of UV rays to the skin when applied to the skin before UV irradiation. However, it has been clarified that a certain type of water-soluble ultraviolet absorber has an effect of suppressing skin inflammation even after irradiation with ultraviolet rays, when it is mixed with an L-ascorbic acid derivative.

The non-steroidal anti-inflammatory drug used in the whitening cosmetic composition of the present invention includes indomethacin, phenylbutazone, ibuprofen, mefenamic acid, diclofenac sodium, bufexamac, nabumetone, etc., but is not limited thereto. Not a thing. These non-steroidal anti-inflammatory drugs are used alone or in combination of two or more.

Examples of the L-ascorbic acid derivative used in the whitening cosmetic composition of the present invention include L-ascorbic acid sulfuric acid ester, L-ascorbic acid phosphoric acid ester magnesium salt, sodium salt, calcium salt and the like. It is not limited to. These L-ascorbic acid derivatives are used alone or in combination of two or more.

The amount of the water-soluble ultraviolet absorber used in the present invention in cosmetics is 0.001 as a total amount relative to the total amount.
-20 wt% (hereinafter referred to as wt%) is preferable, and 0.01 to 10 wt% is more preferable. 0.001wt
If it is less than%, the desired effect is not sufficient, and 20 wt%
Even if it exceeds, you can not expect the improvement of the effect commensurate with the increase,
The feel during use tends to be poor, and it becomes difficult to hold individual dosage forms.

The amount of the non-steroidal anti-inflammatory drug used in the present invention in cosmetics is 0.
001 to 3.0 wt% is preferable, and the compounding amount is 0.001
If it is less than w%, the desired effect of the present invention is not sufficient,
Even if it exceeds 3.0 wt%, it is not possible to expect an improvement in the effect commensurate with the increased amount, the feel during use tends to be poor, and it becomes difficult to hold individual dosage forms.

The amount of the L-ascorbic acid derivative used in the present invention in the cosmetic is preferably 0.5 to 5.0 wt% as the total amount of the cosmetic, and the amount is 0.5.
If it is less than wt%, the desired effect of the present invention is not sufficient, and if it exceeds 5.0 wt%, the effect corresponding to the increase cannot be expected, and the feeling during use tends to be poor, and individual agents It becomes difficult to hold the mold.

In addition to the above raw materials, the cosmetics of the present invention include preservatives such as parabens, anionic surfactants such as sodium cetyl sulfate, polyoxyethylene alkyl ethers,
Nonionic surfactant such as polyoxyethylene fatty acid ester, polyoxyethylene polyhydric alcohol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyhydric alcohol fatty acid ester, polyglycerin fatty acid ester, and cationic surfactant such as tetraalkylammonium salt Agents, betaine type, sulfobetaine type, sulfoamino acid type, amphoteric surfactants such as sodium N-stearoyl-L-glutamate, natural surfactants such as lecithin and lysophosphatidylcholine, pigments such as titanium oxide, dibutyl Antioxidizing agents such as hydroxytoluene may be appropriately blended within the range to achieve the object of the present invention.

Examples of the dosage form of the cosmetic of the present invention include cream, emulsion, lotion and pack. For example, in the case of an emulsion or the like, this cosmetic can be produced by an ordinary method of emulsifying and dispersing an oily phase and an aqueous phase, which are dissolved by heating, and cooling.

[0021]

EXAMPLES The present invention will be described in detail below based on examples and comparative examples.

The test methods of (1) ultraviolet erythema suppression test, (2) skin color lightness reduction suppression test, (3) whitening practical test, (4) light patch test, and (5) sensory test described in Examples are as follows: It is as follows.

(1) UV Erythema Suppression Test A sample application site and a base application site were set on the dorsal skin of 10 dehaired Hartley guinea pigs, and twice the minimum erythema dose (MED) of UV in the UVB region was set. Irradiate two places each. The sample and the base were applied 24 hours before and immediately after the irradiation, and 24 hours after the irradiation, the erythema state was evaluated according to the following criteria.

[0024]

[Table 1]

(2) Skin color lightness reduction suppression test The reference lightness (V0 value, V0 'value) of the sample application planned part and the base application planned part of the upper arm inner skin of 20 test subjects was measured. Thereafter, the same site was continuously irradiated with 1.5 times the minimum erythema dose of ultraviolet rays in the UVB region for 3 days. The sample is irradiated 24
Apply 3 times a day for 1 week consecutively before and immediately after irradiation, and measure the skin lightness (Vn value, Vn 'value) of the skin on the sample-applied part and the base-applied part 1 week after the start of irradiation and apply the base. V0'-Vn 'as the decrease value of the site and V0-Vn as the decrease value of the sample application site were set as ΔV' and ΔV, respectively, and the suppression of the decrease in skin color lightness was evaluated according to the following criteria.

The lightness (V value) of the skin was calculated from the X, Y and Z values obtained by measuring with a high speed spectrocolorimeter. The evaluation is shown by the average value of the evaluation points of 20 test subjects after one week.

[0027]

[Table 2]

(3) Practical whitening test Left forearm flexion side part of the forearm flexion side skin of 20 test subjects exposed to summer sunlight for 3 hours (1.5 hours a day for 2 days) Samples on the skin from the day of exposure to sunlight
The skin was applied to the right forearm flexor lateral region from the day when it was exposed to sunlight, once a day in the morning and once a day for 13 consecutive weeks.

The evaluation was shown by the number of test subjects whose whitening effect was confirmed in the sample application part from the base application part.

(4) Photo-patch test 25 subjects were subjected to closed patch for 24 hours using a patch plate having a diameter of 1.0 cm, which was prepared by applying 0.05 g of the sample to the skin of the forearm flexor side, and then exposed to sunlight in summer. 6 hours (3 a day
For 2 days).

The evaluation was carried out by subject 2 according to the following criteria.
The skin condition of 5 persons was evaluated and judged. Judgment result is irradiation 2
After 4 hours, the number of people was (±) or more.

[0032]

[Table 3]

(5) Sensory test Twenty test subjects evaluated the characteristics of the sample after continuously using the sample for 10 days.

For the evaluation, responding to questionnaire items such as wettability and affinity, "the skin was moistened", "the affinity to the skin was good", "the gloss of the skin was improved", etc. The number of people is shown.

Examples 1 to 3 and Comparative Examples 1 to 6 Skin Lotion In the raw material composition shown in Table 4, the active ingredients were blended as shown in Table 5 to prepare a skin lotion, and the above-mentioned various tests were carried out.

[0036]

[Table 4]

[0037]

[Table 5]

[0038]

[Table 6]

(1) Preparation Method Component B shown in Table 4 is uniformly dissolved in Component D, and Component C is uniformly dissolved in Component A, and then Component A and Component D are uniformly mixed and stirred, and then filled in a container. .

(2) Characteristics The results of various tests are shown in Tables 5 and 6. As shown in Table 5, the comparative examples did not show good results in various tests. On the other hand, the whitening cosmetics of the present invention of Examples 1 to 3 clearly show good results in all tests.
No skin irritation occurred in the tests on human skin.

As described above, the present invention has the effect of preventing skin inflammation due to ultraviolet rays and the prevention of inflammatory pigmentation.
It is obvious to provide a whitening cosmetic having an inhibiting effect.

Continuation of the front page (51) Int.Cl. ⁶ Identification code Office reference number FI technical display location // A61K 7/42

Claims (1)

[Claims] 1. A whitening cosmetic comprising a water-soluble ultraviolet absorber, a nonsteroidal anti-inflammatory drug, and an L-ascorbic acid derivative.